Results from the phase 3 KarMMa-3 trial of ide-cel vs standard of care in previously treated multiple myeloma led to the FDA approval.
Approval Alert | Ide-Cel in Previously Treated Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC
2
Bolstering The Referral Process for CAR T-Cell Therapy in Multiple Myeloma
3
ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes
4
Sirexatamab Regimen May Improve PFS, OS in DKK1-High Colorectal Cancer
5